Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease

Biochemical Pharmacology

Volumn 85, Issue 9, 2013, Pages 1306-1316

  Borrelli, Francesca ^a   Fasolino, Ines ^a   Romano, Barbara ^a   Capasso, Raffaele ^a   Maiello, Francesco ^b   Coppola, Diana ^b   Orlando, Pierangelo ^c   Battista, Giovanni ^b   Pagano, Ester ^a   Di Marzo, Vincenzo ^d   Izzo, Angelo A ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Unit of Cardiology Ospedale dei Pellegrini   (Italy)

^c INSTITUTE OF PROTEIN BIOCHEMISTRY   (Italy)

^d CNR   (Italy)

Author keywords

Cannabigerol; Dinitrobenzene sulphonic acid; Inflammatory bowel disease; Macrophages; Murine colitis; Phytocannabinoids

Indexed keywords

CANNABIGEROL; CYCLOOXYGENASE 2; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; MYELOPEROXIDASE; NITROBENZENE DERIVATIVE; RIMONABANT; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; COLORIMETRY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; INTESTINE EPITHELIUM CELL; MOUSE; NONHUMAN; ORGAN WEIGHT; OXIDATIVE STRESS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CANNABINOIDS; CELL LINE; COLITIS; COLON; CYCLOOXYGENASE 2; EPITHELIAL CELLS; INFLAMMATORY BOWEL DISEASES; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTESTINAL MUCOSA; KI-67 ANTIGEN; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED ICR; NITRIC OXIDE SYNTHASE TYPE II; PERMEABILITY; PEROXIDASE; REACTIVE OXYGEN SPECIES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SUPEROXIDE DISMUTASE;

EID: 84875726038     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.01.017     Document Type: Article

References (57)

1. B. Khor, A. Gardet, and R.J. Xavier Genetics and pathogenesis of inflammatory bowel disease Nature 474 2011 307 317
2. E. Glocker, and B. Grimbacher Inflammatory bowel disease: is it a primary immunodeficiency Cell Mol Life Sci 69 2012 41 48
3. J. Cosnes, C. Gower-Rousseau, P. Seksik, and A. Cortot Epidemiology and natural history of inflammatory bowel diseases Gastroenterology 140 2011 1785 1794
4. N.A. Molodecky, I.S. Soon, D.M. Rabi, W.A. Ghali, M. Ferris, and G. Chernoff Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review Gastroenterology 142 2012 46 54 e42
5. D. Burger, and S. Travis Conventional medical management of inflammatory bowel disease Gastroenterology 140 2011 1827 1837 e2
6. W. Blonski, A.M. Buchner, and G.R. Lichtenstein Inflammatory bowel disease therapy: current state-of-the-art Curr Opin Gastroenterol 27 2011 346 357
7. A.A. Izzo, and M. Camilleri Cannabinoids in intestinal inflammation and cancer Pharmacol Res 60 2009 117 125
8. M. Alhouayek, and G.G. Muccioli The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity Trends Mol Med 18 2012 615 625
9. T. Naftali, L.B. Lev, D. Yablecovitch, E. Half, and F.M. Konikoff Treatment of Crohn's disease with cannabis: an observational study Isr Med Assoc J 13 2011 455 458
10. S. Lal, N. Prasad, M. Ryan, S. Tangri, M.S. Silverberg, and A. Gordon Cannabis use amongst patients with inflammatory bowel disease Eur J Gastroenterol Hepatol 23 2011 891 896
11. A. Lahat, A. Lang, and S. Ben-Horin Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study Digestion 85 2012 1 8
12. F. Borrelli, G. Aviello, B. Romano, P. Orlando, R. Capasso, and F. Maiello a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis J Mol Med 87 2009 1111 1121
13. J.M. Jamontt, A. Molleman, R.G. Pertwee, and M.E. Parsons The effects of delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis Br J Pharmacol 60 2010 712 723
14. R. Schicho, and Storr M. Topical Systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice Pharmacology 89 2012 149 155
15. C.E. Turner, M.A. Elsohly, and E.G. Boeren Constituents of Cannabis sativa L. XVII. A review of the natural constituents J Nat Prod 43 1980 169 234
16. R. Mechoulam, A. Shani, H. Edery, and Y. Grunfeld Chemical basis of hashish activity Science 169 1970 611 612
17. A.A. Izzo, F. Borrelli, R. Capasso, V. Di Marzo, and R. Mechoulam Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb Trends Pharmacol Sci 30 2009 515 527
18. A.J. Hill, C.M. Williams, B.J. Whalley, and G.J. Stephens Phytocannabinoids as novel therapeutic agents in CNS disorders Pharmacol Ther 133 2012 79 97
19. A. Ligresti, A.S. Moriello, K. Starowicz, I. Matias, S. Pisanti, and L. De Petrocellis Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma J Pharmacol Exp Ther 318 2006 1375 1387
20. G. Appendino, S. Gibbons, A. Giana, A. Pagani, G. Grassi, and M. Stavri Antibacterial cannabinoids from Cannabis sativa: a structure-activity study J Nat Prod 71 2008 1427 1430
21. B.K. Colasanti A comparison of the ocular and central effects of delta 9-tetrahydrocannabinol and cannabigerol J Ocul Pharmacol 6 1990 259 269
22. E.M. Rock, J.M. Goodwin, C.L. Limebeer, A. Breuer, R.G. Pertwee, and R. Mechoulam Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews Psychopharmacology (Berl) 215 2011 505 512
23. L. De Petrocellis, A. Ligresti, A.S. Moriello, M. Allarà, T. Bisogno, and S. Petrosino Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes Br J Pharmacol 163 2011 1479 1494
24. L.R. Ruhaak, J. Felth, P.C. Karlsson, J.J. Rafter, R. Verpoorte, and L. Bohlin Evaluation of the cyclooxygenase inhibiting effects of six major cannabinoids isolated from Cannabis sativa Biol Pharm Bull 34 2011 774 778
25. M.G. Cascio, L.A. Gauson, L.A. Stevenson, R.A. Ross, and R.G. Pertwee Evidence that the plant annabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist Br J Pharmacol 159 2010 129 141
26. F. Massa, G. Marsicano, H. Hermann, A. Cannich, K. Monory, and B.F. Cravatt The endogenous cannabinoid system protects against colonic inflammation J Clin Invest 113 2004 1202 1209
27. G. D'Argenio, M. Valenti, G. Scaglione, V. Cosenza, I. Sorrentini, and V. Di Marzo Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation FASEB J 20 2006 568 570
28. M. Osanai, N. Nishikiori, M. Murata, H. Chiba, T. Kojima, and N. Sawada Cellular retinoic acid bioavailability determines epithelial integrity: Role of retinoic acid receptor alpha agonists in colitis Mol Pharmacol 71 2007 250 258
29. S.E. Goldblum, K.M. Wu, and M. Jay Lung myeloperoxidase as a measure of pulmonary leukostasis in rabbits J Appl Physiol 59 1985 1471 1480
30. H. Kuthan, H.J. Haussmann, and J. Werringloer A spectrophotometric assay for superoxide dismutase activities in crude tissue fractions Biochem J 237 1986 175 180
31. G. Aviello, F. Borrelli, F. Guida, B. Romano, K. Lewellyn, and M. De Chiaro Ultrapotent effects of salvinorin A, a hallucinogenic compound from Salvia divinorum, on LPS-stimulated murine macrophages and its anti-inflammatory action in vivo J Mol Med 89 2011 891 902
32. R.H. Whitehead, P.S. Robinson, J.A. Williams, W. Bie, A.L. Tyner, and J.L. Franklin Conditionally immortalized colonic epithelial cell line from a Ptk6 null mouse that polarizes and differentiates in vitro J Gastroenterol Hepatol 23 2008 1119 1124
33. L. De Petrocellis, P. Orlando, A.S. Moriello, G. Aviello, C. Stott, and A.A. Izzo Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation Acta Physiol 204 2012 255 266
34. J. Gálvez, M. Garrido, M. Merlos, M.I. Torres, and A. Zarzuelo Intestinal anti-inflammatory activity of UR-12746, a novel 5-ASA conjugate, on acute and chronic experimental colitis in the rat Br J Pharmacol 130 2000 1949 1959
35. J.E. Krawisz, P. Sharon, and W.F. Stenson Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models Gastroenterology 87 1984 1344 1350
36. A. Alhamoruni, K.L. Wright, M. Larvin, and S.E. O'Sullivan Cannabinoids mediate opposing effects on inflammation-induced intestinal permeability Br J Pharmacol 165 2012 2598 2610
37. R. Capasso, F. Borrelli, G. Aviello, B. Romano, C. Scalisi, and F. Capasso extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice Br J Pharmacol 154 2008 1001 1008
38. D. De Filippis, G. Esposito, C. Cirillo, M. Cipriano, B.Y. De Winter, and C. Scuderi Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis PLoS ONE 6 2011 e28159
39. A.A. Izzo, R. Capasso, G. Aviello, F. Borrelli, B. Romano, and F. Piscitelli Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice Br J Pharmacol 166 2012 1444 1460
40. Romano B, Borrelli F, Fasolino I, Capasso R, Piscitelli F, Cascio M, Pertwee R, Coppola D, Vassallo L, Orlando P, Di Marzo V, Izzo A. The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis. Br J Pharmacol. 2013 Feb 4. http://dx.doi.org/ 10.1111/bph.12120 [Epub ahead of print].
41. S.N. Andersen, T.O. Rognum, A. Bakka, and O.P. Clausen Ki-67: a useful marker for the evaluation of dysplasia in ulcerative colitis Mol Pathol 51 1998 327 332
42. Madsen K. Combining T cells and IL-10: a new therapy for Crohn's disease Gastroenterology 123 2002 2140 2144
43. W. Strober, and I.J. Fuss Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases Gastroenterology 140 2011 1756 1767
44. G. Barbara, Z. Xing, C.M. Hogaboam, and J. Gauldie Collins SM. Interleukin 10 gene transfer prevents experimental colitis in rats Gut 46 2000 344 349
45. R. Ito, M. Shin-Ya, T. Kishida, A. Urano, R. Takada, and J. Sakagami Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice Clin Exp Immunol 146 2006 330 338
46. F. Lamine, H. Eutamène, J. Fioramonti, L. Buéno, and V. Théodorou Colonic responses to Lactobacillus farciminis treatment in trinitrobenzene sulphonic acid-induced colitis in rats Scand J Gastroenterol 39 2004 1250 1258
47. G. Kolios, V. Valatas, and S.G. Ward Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle Immunology 113 2004 427 437
48. J.L. Wallace, and P.R. Devchand Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense Br J Pharmacol 145 2005 275 282
49. R.M. Palmer, D.S. Ashton, and S. Moncada Vascular endothelial cells synthesize nitric oxide from L-arginine Nature 333 1988 664 666
50. S. Moncada, A. Higgs, and R. Furchgott International Union of Pharmacology Nomenclature in Nitric Oxide Research Pharmacol Rev 49 1997 137 142
51. 9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour Psychopharmacology (Berl) 219 2012 859 873
52. F. Pollastro, O. Taglialatela-Scafati, M. Allarà, E. Muñoz, V. Di Marzo, and L. De Petrocellis Bioactive prenylogous cannabinoid from fiber hemp (Cannabis sativa) J Nat Prod 74 2011 019 2022
53. M.A. Engel, A. Leffler, F. Niedermirtl, A. Babes, K. Zimmermann, and M.R. Filipović P mediate colitis in mice Gastroenterology 141 2011 1346 1358
54. A. Bai, N. Lu, Y. Guo, J. Chen, and Z. Liu Modulation of inflammatory response via alpha2-adrenoceptor blockade in acute murine colitis Clin Exp Immunol 156 2009 353 362
55. E. D'Aldebert, N. Cenac, P. Rousset, L. Martin, C. Rolland, and K. Chapman Transient receptor potential vanilloid 4 activated inflammatory signals by intestinal epithelial cells and colitis in mice Gastroenterology 140 2011 275 285
56. Watterlot L, Rochat T, Sokol HC, Cherbuy I, Bouloufa F, Lefevre JJ, et al. Bermudez-Humaran. Intragastric administration of a superoxide dismutase-producing recombinant Lactobacillus casei BL23 strain attenuates DSS colitis in mice. Int J Food Microbiol 2010;144:35-41.
57. Kruidenier L, Verspaget HW. Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease - radicals or ridiculous? Aliment Pharmacol Ther 2002;16:1997-2015.